29 June 2020
: Case report 
Mycobacterium abscessus Associated Peritonitis with CAPD Successfully Treated Using a Linezolid and Tedizolid Containing Regimen Suggested Immunomodulatory Effects
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Patient complains / malpractice, Rare disease
Masafumi SekiACDEFG, Yasuhiro KamiokaBC, Kazuki TakanoBCD, Haruka ImaiBC, Mai ShojiBC, Maya HariuBCD, Yukari KabutoyaB, Yuji WatanabeABCDDOI: 10.12659/AJCR.924642
Am J Case Rep 2020; 21:e924642
Table 2. Reported peritonitis cases where Mycobacterium abscessus was isolated.
| Study | Patients (n) | Male/Female | Age (yrs) | Underlying diseases | Major pathogen | Antibiotics | Survived/death |
|---|---|---|---|---|---|---|---|
| Ding et al. []8 | 11 | 6/5 | 64.5 | Malignancy (73%) | (27%) | Unknown | 1 patient survived more than 1 year |
| Kleinpeter and Krane []9 | 2 | 1/1 | 63/28 | Diabetes/nephritis | / | CAM and/or AMK | Both survived |
| Yoshimura et al. []10 | 1 | 1/0 | 56 | Diabetes | CAM and IPM/CS | Survived | |
| yrs – years; ; CAM – clarithromycin; AMK – amikacin; IMP/CS – imipenem/cilastatin. | |||||||